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Summary at a Glance 
The soluble receptor for advanced glycation end products (sRAGE) plays an important role in 
inflammation. This study identified that sRAGE is present at higher concentrations in the lung 
compared to blood of children, is developmentally regulated and varies with the pattern of 
lung inflammation. 
 
ABSTRACT  
Background and objective: The soluble receptor for advanced glycation end products 
(sRAGE) plays an important role in inflammation. Few studies have looked at sRAGE levels 
in human lungs, and there is no information in children. Therefore this study aimed to 
compare bronchoalveolar lavage fluid (BALF) and plasma sRAGE concentrations in children 
in relation to age and inflammation. 
 
Methods: BAL was performed in 76 children, and BALF and plasma sRAGE levels were 
determined by ELISA. 
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Results: sRAGE levels were four-fold higher in BALF than in plasma (p<0.001). BALF 
sRAGE was inversely proportional to age (r=-0.333, p=0.008) and serum IgA (r=-0.283, 
p=0.028). Plasma sRAGE showed a positive correlation to the percentage of BAL 
macrophages and negative correlation to the percentage of neutrophils and lymphocytes 
(p<0.05).  Multivariate linear regression analysis identified that the percentage of BAL 
lymphocytes and neutrophils were significant independent predictors of plasma sRAGE 
levels, while age and the percentage of BAL macrophages independently predicted BALF 
sRAGE levels. 
 
Conclusions: In children, sRAGE is present at higher concentrations in the lung compared to 
blood. It appears that sRAGE varies with age and hence future studies of sRAGE in paediatric 
lung disease require age-matching. The significant relationship between sRAGE and lung 
inflammation warrants further research. 
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INTRODUCTION 
Early childhood is marked by rapid lung growth and by vulnerability to respiratory infections 
and inflammatory disorders including pneumonia, bronchiolitis and asthma. This vulnerability 
is probably due in part to immaturity of innate and adaptive immunity 1. Current 
understandings of the mechanisms that regulate inflammatory pathways and immune function 
in childhood are incomplete. 
 
There has been much recent interest in the receptor for advanced glycation end products 
(RAGE) which plays an important but complex role in many inflammatory responses. RAGE 
is expressed in many organs including the lung, and mediates responses to cell injury induced 
by a variety of stimuli including oxidative stress and hypoxia 2, 3. The many ligands for RAGE 
include advanced glycation end-product modified proteins, serum amyloid A, amphoterin and 
members of the S100 protein family. Binding of these ligands to RAGE on cell membranes 
initiates a pro-inflammatory cascade. RAGE has several isoforms including a soluble form 
known as sRAGE that functions as a decoy receptor, mopping up RAGE ligands in the extra-
cellular fluid and thereby protecting against tissue injury and inflammation. These protective 
properties have been shown in a variety of animal models, where treatment with sRAGE can 
successfully reverse inflammation 4, 5. 
 
Both membrane bound RAGE and sRAGE are expressed constitutively in normal adult lung 
tissue, even in the absence of inflammation or tissue injury 6-8, perhaps because the lung is 
constantly exposed to a multitude of environmental stimuli. RAGE expression appears to be 
crucial for normal type I alveolar epithelial cell function, so RAGE may also play an 
important homeostatic role in the lung under steady state conditions.  
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The role of RAGE and sRAGE in lung pathology appears complex. Acute lung injury is 
associated with increased concentrations of RAGE in bronchoalveolar lavage (BAL) fluid and 
plasma 9-12, while in animal models of pneumonia, RAGE appears to impair host defence 13. 
Membrane RAGE and sRAGE are reduced in patients with idiopathic pulmonary fibrosis 7, 14. 
Plasma sRAGE is also reduced in chronic obstructive pulmonary disease 15, and there is some 
evidence that RAGE may have a protective role in animal models of lung disease 7, 14.  
 
Little is known regarding RAGE expression in the lungs of children, though this might be 
relevant to a number of pulmonary diseases of children. Studies in rats indicate that 
membrane bound RAGE and sRAGE are expressed to a lesser degree in lungs from neonatal 
rats than adult lungs 16. Expression of both RAGE isoforms increases during post-natal life 16, 
though this has not been examined in humans.  
 
The aims of the current study were (i) to examine BAL fluid and plasma sRAGE in children 
of various ages and (ii) to determine whether sRAGE is associated with lung inflammatory 
cells, age and humoral immune function. 
 
METHODS 
Subject recruitment 
Between March 2008 and September 2009, 76 children who were undergoing bronchoscopy 
for a clinical indication including evaluation of chronic cough and assessment of the upper 
airways were enrolled into the study. The latter group of children have no history of current or 
chronic cough and had stridor. Children were recruited from the respiratory outpatient 
department, Royal Children’s Hospital, Brisbane and were excluded if they were thought to 
have recurrent aspiration (presence of swallowing disorder or cerebral palsy), A
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immunodeficiency, prematurity (<37 weeks gestation), or a specific underlying respiratory 
disorder (such as cystic fibrosis, interstitial lung disease, bronchiectasis, or more than 2 prior 
episodes of pneumonia). The study was approved by the Royal Children’s Hospital Ethics 
Committee, Brisbane, Australia and parents consented for all samples to be used. 
 
Bronchoscopy and BAL 
Flexible bronchoscopy was performed transnasally under general anaesthesia as previously 
described 17 and was well tolerated in all subjects. BAL was obtained as per the 
recommendations of the ERS Task Force on BAL in children 18. The first aliquot (1ml/kg, 
max 10mls of normal saline instilled) was used for microbiological examination and detection 
of bacteria, fungi and viruses using standard methodology. The second and third aliquots 
(total 2mls/kg, max 20 mls) were pooled for total cell count and differential leukocyte counts. 
The remaining BAL fluid (from pooled 2nd and 3rd aliquots) was stored at -80°C for 
subsequent batch analysis of sRAGE levels. Recorded information included yield from BAL, 
macroscopic appearances and the presence of any anatomical abnormalities.  
 
 
 
Blood sampling 
At recruitment a peripheral blood sample was taken and immunoglobulins (IgA, IgM, IgE and 
IgG) were measured by Queensland Pathology using commercial auto-analysers. A second 
sample was taken at bronchoscopy and plasma was stored at -80°C for later batch analysis of 
sRAGE levels. 
 
Measurement of sRAGE A
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Concentrations of sRAGE in BAL fluid and plasma were determined by commercial ELISA 
(R&D Systems, Minneapolis, USA) according to manufacturer’s directions. Detection limit 
for the assay was 19.5 pg/ml. 
 
Statistical analysis 
Data is presented as the median (interquartile range) unless otherwise stated. SPSS (IBM 
SPSS Inc, Chicago) was used for data analysis and p<0.05 was considered statistically 
significant. Group differences were assessed by Mann-Whitney U Test, while paired samples 
were compared by Wilcoxon Signed-Rank Test. Correlations between variables were 
determined using Spearman’s rho. For simple and multiple linear regression analysis, 
variables were examined for normal distribution and if necessary were natural log-
transformed before further analysis. Simple linear regression analysis was initially used to 
evaluate the relationship between variables and sRAGE. Those variables in which p<0.1 were 
then subjected to multiple linear regression analysis followed by interaction and residual 
analyses. 
 
 
 
RESULTS 
Subject Characteristics and BAL differential cell counts 
Full characteristics of the study subjects are outlined in Table 1. Briefly, the median age of the 
children was 20.1 (11.8 – 41) months. Within the lung there was range in the number and 
pattern of inflammatory cells present, with a median total cell count (TCC) of 150 (94 – 300) 
cells/ml and 14% (5 - 53) neutrophils and 70% (34 - 87) macrophages in the BALF of the 
children. Bacterial pathogens (at growth ≥105 cfu/ml) were detected in the BALF of 53 (70%) A
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children. There was no difference in the age of the children being assessed for chronic cough 
compared to those having an upper airway assessment (data not shown).  
 
BALF sRAGE levels are higher than plasma levels, and are negatively correlated with 
age 
Matched BALF and plasma samples were available from 62 children (82% of cohort). There 
was no difference in demographic factors between the children with and without matched 
plasma and BALF. sRAGE levels were approximately 4 fold higher (p<0.001) in BALF 
compared to plasma (Figure 1). Surprisingly, there was no statistically significant association 
between plasma and BALF sRAGE levels (r=0.160 p=0.213). We next investigated how these 
levels varied with the age of the children, and found a significant inverse association between 
BALF sRAGE levels and age (p=0.008, Figure 2A). However, this relationship was not seen 
between plasma sRAGE and age (Figure 2B).  
 
Relationships between BALF and plasma sRAGE levels and inflammatory cells  
There was no relationship between the concentration of sRAGE in plasma or BALF and the 
BAL TCC (Table 2). However, there was a significant inverse association between plasma 
sRAGE and the percentage of lymphocytes (p=0.007) and neutrophils (p=0.008, Table 2) in 
the BAL differential, such that the lowest plasma sRAGE concentrations were observed in 
those with greater degrees of BAL lymphocytosis and neutrophilia. In contrast, plasma 
sRAGE was positively correlated with the percentage of BAL macrophages (p=0.012). There 
was no relationship between any inflammatory cells in BAL and BALF sRAGE levels (Table 
2). Similarly, there was no relationship between any inflammatory cell differentials in the 
blood and BALF or plasma sRAGE levels (Table 2).  There was also no difference in the 
concentration of sRAGE measured in either the BALF or plasma between children who did or A
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did not have positive microbial cultures (defined as growth ≥105 cfu/ml, Table 2). Finally, 
BALF cytokine levels were also assessed. IL-6 in BAL fluid was not associated with BALF 
sRAGE (r=-0.057, p=0.66) and IL-8 was very weakly inversely proportional to BALF 
sRAGE (r=-0.259, p=0.05, data not shown).   
 
BALF sRAGE levels are negatively correlated with serum IgA levels  
There was a weak negative correlation between BALF sRAGE and serum IgA (r = -0.283, 
p=0.028), but this was not seen with either IgG or IgM (Table 3). Similarly, there was no 
relationship between plasma sRAGE levels and any serum antibody (Table 3).   
 
Variables associated with plasma and BALF sRAGE  
To better understand the relationship between plasma or BALF sRAGE levels and age, sex, 
serum immunoglobulin levels, TCC and BAL cellularity, regression modelling was 
performed. Simple univariate linear regression of data from all subjects showed that plasma 
sRAGE was slightly higher in male children, was inversely predicted by the percentage of 
BALF lymphocytes and neutrophils and positively predicted by the percentage of 
macrophages in the BAL (Table 4). When these variables were included in a multivariate 
linear regression analysis, only the percentage of lymphocytes and neutrophils remained as 
the strongest independent predictors of plasma sRAGE levels (Table 4). There was no 
association with immunoglobulin levels, age or the total BAL cell count. Also, there was no 
association between BALF sRAGE and either the intensity or type of bacterial pathogens 
isolated from BALF, regardless of whether it was analysed by the total number of organisms 
grown, or where infection (≥105 cfu/ml) was analysed as a dichotomous variable (data not 
shown). 
 
A
cc
ep
te
d 
A
rti
cl
e
 © 2012 The Authors 
Respirology © 2012 Asian Pacific Society of Respirology 
10 
Simple univariate linear regression analysis identified that the main predictors of BALF 
sRAGE levels were male sex, age, serum IgA levels and the percentage of macrophages in the 
BAL (Table 5). When these variables were included in a multivariate linear regression model, 
only the percentage of macrophages and age remained as independent predictors (Table 5). 
There was no association with TCC, or immunoglobulin levels, other than those previously 
mentioned. 
 
 
DISCUSSION 
In this study we measured sRAGE levels in matched samples from the lungs and circulation 
of children. The key findings to emerge were that sRAGE levels were considerably higher in 
BALF than in plasma, and that BALF, but not plasma, sRAGE levels varied in relation to age. 
Furthermore, multivariate linear regression analysis identified that sRAGE levels within both 
the circulation and lung were associated with the profile of lung inflammatory cells, 
highlighting a potentially important role for sRAGE in lung inflammation.  
 
While several recent studies have examined sRAGE in adult lung diseases 7, 9, 14, 15, 19, there 
are no publications on this important and complex inflammatory axis in children. In addition, 
few investigators have simultaneously measured sRAGE in both lung and blood 
compartments 20, and there are no published studies on sRAGE in BAL of children. It is clear 
from the data shown in Figure 1 that sRAGE is present at much higher concentrations in 
BALF than in plasma. This is not surprising, given that both membrane bound RAGE and 
sRAGE are expressed abundantly in normal adult lung tissue 6-8.  Some of the sRAGE in 
plasma is likely to have originated from the lung. However, it is likely that other tissues also 
contribute to plasma sRAGE, and the lack of a statistically significant association between A
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BALF and plasma concentrations suggests it is too simplistic to attribute plasma sRAGE 
levels as merely a consequence of leakage of sRAGE from the lung. Proving the ‘over spill’ 
of inflammatory mediators from the lung into the circulation is difficult, as discussed recently 
21
, so we propose that measuring sRAGE in both the lung and blood compartments provides 
complementary information. 
 
Our finding that BALF sRAGE varied in relation to age (Figure 2 and Table 5) suggests that 
it may be developmentally regulated. To our knowledge there has only been one other study 
looking at sRAGE in relation to age, a murine study comparing neonatal and adult sRAGE 
expression 16.  While these investigators showed that sRAGE expression was lower in 
neonatal than in adult mice, sRAGE was measured by western blotting which can be difficult 
to accurately quantitate. Interestingly, the investigators reported that sRAGE glycosylation 
patterns vary with age which may account for their observations. It is unknown if age-related 
differences in glycosylation exist in humans, but as we measured sRAGE using a commercial 
ELISA which detects the same sRAGE antigen over the entire cohort we believe that BALF 
sRAGE is developmentally regulated. It is intriguing that BALF sRAGE is inversely 
proportional to serum IgA, which may suggest that sRAGE is produced at high levels in the 
lung at a time in early childhood when the main mucosal antibody, IgA, is relatively deficient. 
Hence, future studies of sRAGE in children need to consider age as an important variable.  
 
It is notable that BALF sRAGE levels showed an approximately 500 fold range in 
concentration compared to the 20 fold range in blood sRAGE. It is unknown why BALF 
sRAGE shows such a high degree of variability across the cohort, and while age would 
account for some of the spread, further investigations will be required to more accurately 
address this issue. However a high degree of variability was also found in a study that A
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evaluated the effect of mechanical ventilation on BALF sRAGE in adults (range from 0-2500 
pg/ml) 20. This study has highlighted the strong statistical association between lung 
inflammation and both BALF and plasma sRAGE (Tables 4 & 5). Inflammatory cell 
populations in the lung are dependent on differentiation within bone marrow, trafficking 
through the circulation and recruitment to the lung, and plasma sRAGE might be involved in 
some or all of these processes. The strong association between lung inflammation and BALF 
and plasma sRAGE may also suggest that either sRAGE is being produced or utilised in 
response to current inflammation. Alternatively, it may be expressed in response to current 
infection as previously suggested 12, although our data in children does not appear to support 
this (Table 2). The extent to which variations in lung and blood sRAGE contribute to the 
pathogenesis of lung inflammation or are instead a downstream consequence of lung 
inflammation is an unresolved issue that warrants further research. It is noteworthy that 
variations in the AGER gene that regulates RAGE expression appear to be risk factors for 
some diseases 22-26. Longitudinal studies will be required to more accurately define if 
variations in both plasma and BALF sRAGE levels are indeed risk factors for respiratory 
infections, inflammation and disease in children.  
 
There are a number of limitations of the current study that should be acknowledged. While it 
would have been ideal to have recruited a group of truly healthy children for the study, there 
are considerable ethical issues around performing bronchoscopy on asymptomatic children. 
Therefore, although 15 children did not have any airway inflammation (ie bronchoscopy was 
to performed to evaluate upper airway lesions), we acknowledge that our cohort may not be 
reflective of the normal healthy situation.  Nonetheless, our study provides an important 
foundation for further investigation of the role of sRAGE in airway inflammatory conditions 
in children. A
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In conclusion, BALF sRAGE is present at higher concentrations than circulating plasma 
sRAGE and appears to vary with age. Hence comparative studies of sRAGE in children with 
lung disease should include age-matching of cases and controls. The extent to which 
variations in lung and blood sRAGE contribute to the pathogenesis of lung inflammation or 
are instead a downstream consequence of lung inflammation is an unresolved issue that 
warrants further research. 
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Table 1: Subject Characteristics 
 
Study Subject Characteristics 
(n=76) 
Age, median (IQR) months 20.1 (11.8 – 41.0) 
Male, n (%) 53 (70) 
Reasons for bronchoscopy, n (%)  
     Assessment of upper airways  15 (20) 
     Presence of lower respiratory symptoms  
       (cough or wheeze) 
61 (80) 
BALF characteristics  
     TCC, median (IQR) 150 (94 – 330) 
     %macrophages, median (IQR) 70 (34 – 87) 
     %lymphocytes, median (IQR) 9 (5 – 12) 
     %neutrophils, median (IQR) 14 (5 – 53) 
     Number of bacterial pathogens grown at ≥105 
       cfu/ml, median (IQR) 
2 (0 - 3) 
Serum characteristics  
     IgA (g/l), median (IQR) 0.5 (0.2 – 0.7) 
     IgG (g/l), median (IQR) 6.4 (4.9 – 8.2) 
     IgM (g/l), median (IQR) 0.8 (0.6 – 1.1) 
IQR= interquartile range, 
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Table 2: Non-parametric correlations between sRAGE levels and inflammatory cells  
 Plasma sRAGE BALF sRAGE 
TCC r = -0.096, p=0.416 r = 0.007, p=0.955 
%macrophages in BALF r = 0.293, p=0.012 r = 0.142, p=0.280 
%lymphocytes in BALF r = -0.311, p=0.007 r = -0.007, p=0.954 
%neutrophils in BALF r = -0.306, p=0.008 r = -0.091 p=0.492 
Number of bacterial pathogens 
with growth ≥105 cfu/ml 
r = 0.0320, p = 0.784 r = -0.0694, p= 0.591 
%neutrophils in blood r = -0.198, p=0.092 r = -0.242, p=0.064 
%monocytes in blood r = -0.209, p=0.076 r = -0.022, p=0.867 
%lymphocytes in blood r = -0.056, p=0.637 r = 0.145, p=0.274 
White blood cell count  r = -0.176, p=0.139 r = 0.050, p=0.711 
 
 
Table 3: Correlations between sRAGE levels and serum immunoglobulin levels  
 Plasma sRAGE BALF sRAGE 
IgA r = -0.203, p=0.084 r = -0.283, p=0.028 
IgM r = -0.102, p=0.391 r = -0.157, p=0.230 
IgG r = -0.161, p=0.165 r = -0.172, p=0.180 
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Table 4: Linear regression analysis of plasma sRAGE levels as the dependant variable  
Univariate analysis β p 95% CI for β 
Male sex -0.265 0.093 -0.577 – 0.045 
* % lymphocytes in BALF -0.265 0.004 -0.445 - -0.085 
* % neutrophils in BALF -0.146 0.008 -0.254 - -0.039 
* % macrophages in BALF 0.172 0.063 -0.009 – 0.353 
    
Multivariate analysis β p 95% CI for β 
* % lymphocytes in BALF -0.222 0.018 -0.405 - -0.039 
* % neutrophils in BALF -0.119 0.028 -0.226 - -0.013 
 
Variables marked with (*) and sRAGE were natural log-transformed. Only variables with 
p<0.01 are shown in the table. r2 of the multivariate linear regression = 0.166. 
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Table 5 : Linear regression analysis of BALF sRAGE levels as the dependant variable  
Univariate analysis β p 95% CI for β 
Male sex -0.614 0.045 -1.213 - -0.015 
* Age (months) -0.322 0.030 -0.611 - -0.033 
* plasma IgA -0.409 0.013 -0.729 - -0.088 
* % macrophages in BALF 0.591 <0.001 0.295 – 0.887 
    
Multivariate analysis β p 95% CI for β 
* Age (months) -0.272 0.042 -0.535 - -0.010 
* % macrophages in BALF 0.561 <0.001 0.271 – 0.850 
 
Variables marked with (*) and sRAGE were natural log-transformed. Only variables with 
p<0.01 are shown in the table. r2 of the multivariate linear regression = 0.279.  
 
 
FIGURE LEGENDS 
Figure 1: BALF and plasma sRAGE levels 
sRAGE levels were measured in matched (n=62) BALF and plasma samples, and are 
presented as box and whisker plots with significant differences indicated. 
 
Figure 2: BALF and plasma sRAGE levels plotted against age 
BALF (A) and plasma (B) sRAGE levels are shown against the age of the children at 
sampling. Data are presented a scatter plots with significant correlations indicated. A
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